Chemical Name:P1,P4-Diuridine 5-tetraphosphate tetrasodium salt
- CAS No.211427-08-6
- Molecular Formula:C18H22N4Na4O23P4
- Formula Weight:878.2344
Synonyms:INS365;211427-08-6;Uridine 5-(pentahydrogen tetraphosphate), P-5ester with uridine, tetrasodium salt;Ins 365;tetrasodium 1-[(2R,3R
*The following content is generated by AI and is for reference only.
Diquafosol tetrasodium, identified by the CAS number 211427-08-6, is a potent synthetic nucleotide analog specifically designed for the treatment of dry eye disease. This compound acts as a selective P2Y2 receptor agonist, playing a critical role in stimulating the secretion of both aqueous tears and mucus from ocular surface cells. By mimicking endogenous uridine triphosphate (UTP), Diquafosol enhances the production of mucins and fluid, thereby improving the stability of the tear film and alleviating symptoms associated with severe dry eye conditions such as keratoconjunctivitis sicca.
The chemical structure of Diquafosol tetrasodium features a modified nucleotide backbone where sodium counterions ensure solubility and bioavailability in ophthalmic formulations. Its molecular formula reflects this salt form, typically represented to account for the four sodium atoms replacing acidic protons on the phosphate groups. The high purity grade, often marketed as "99% up GMP," indicates that the substance meets strict Good Manufacturing Practice standards required for pharmaceutical applications. This ensures consistency in potency, sterility, and safety profiles essential for direct application to the sensitive ocular surface.
In clinical practice, Diquafosol tetrasodium is formulated into ophthalmic solutions for topical administration. It addresses the dual pathology of dry eye disease: insufficient tear volume and compromised mucin layer integrity. Unlike artificial tears which merely supplement moisture, this agent actively promotes physiological secretion, offering a more sustainable therapeutic effect. Research suggests its efficacy in reducing corneal epithelial defects and improving patient comfort scores significantly over placebo treatments. Furthermore, its mechanism avoids systemic absorption issues common with oral medications, minimizing potential side effects while maximizing local efficacy.
As a key active pharmaceutical ingredient (API) within the ophthalmology sector, Diquafosol represents a significant advancement in managing chronic dry eye disorders. Manufacturers adhere to rigorous quality control measures, including DMF (Drug Master File) submissions, to validate the synthesis process and raw material quality. The availability of high-purity Diquafosol tetrasodium supports the development of next-generation eye drops capable of restoring ocular homeostasis effectively. For healthcare professionals and patients alike, it stands as a vital tool in preserving vision quality and enhancing daily life for individuals suffering from aqueous-deficient or evaporative dry eye syndromes.
(All Rights Reserved)
